RZLT stock news · Rezolute, Inc.
Get alerts for RZLT
Follow Rezolute, Inc. (RZLT) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RZLTMorgan Stanley is helping Rezolute, Inc. raise about $100 million by managing its securities offering.
NeutralRezolute expects to raise about $100 million before fees through a securities offering, expected to close around November 16. The cash could support its work, but the source gives no security type or final proceeds, leaving no clear change to its outlook.
Rezolute has raised $100 million and is moving forward with selling ersodetug for tumor hyperinsulinism.
Good or bad for RZLT?Rezolute has raised $100 million and is moving forward with selling ersodetug for tumor hyperinsulinism.
Good or bad for RZLT?Rezolute, Inc. says its Phase 3 study showed promising results for treating tumor hyperinsulinism.
Good or bad for RZLT?Rezolute, Inc. shares news about patient sign-ups for its upLIFT study.
NeutralRezolute announced an enrollment update for its upLIFT study, but gave no count or result. The filing does not show a change in the company's prospects.
The FDA suggests a meeting about Rezolute's drug for a rare blood sugar problem, even though it didn't hit all its goals.
NeutralThe FDA recommended a meeting about Rezolute’s drug, but its main trial goals were missed and approval is not promised. Together, these facts leave the company’s outlook unchanged.
Rezolute, Inc. shares news about talks with the FDA.
NeutralRezolute reported ongoing FDA discussions about its sunRIZE trial and possible next steps. The filing gives no FDA decision or trial result, so it does not change the company's prospects.
Rezolute, Inc. shares its financial results for the last quarter and year ending June 30, 2026.
NeutralRezolute filed an 8-K attaching a press release on fiscal 2026 results; the filing text here shows no numbers, so it does not change our view of the company.